

Sumitomo to market Johnson & Johnson's schizophrenia drug in Japan

21 January 2025 | News

Announces agreement on co-promotion collaboration partner for marketing of PPLAT XEPLION and XEPLION TRI in Japan



Sumitomo Pharma has concluded a co-promotion collaboration partner agreement with Johnson & Johnson (J&J) in Japan of the long-acting antipsychotic medication XEPLION Aqueous Suspension for IM Injection 25 mg Syringe, 50 mg Syringe, 75 mg Syringe, 100 mg Syringe and 150 mg Syringe, which are indicated for schizophrenia, as well as XEPLION TRI Aqueous Suspension for IM Injection 175 mg Syringe, 263 mg Syringe and 350 mg Syringe and 525 mg Syringe, which are indicated for schizophrenia (only when appropriate treatment has been conducted with paliperidone every four weeks), currently marketed by Janssen Pharma in Japan.

Sumitomo Pharma focuses on the area of Psychiatry & Neurology as one of its priority disease areas for research and development, as well as focus areas in the Japanese market. Sumitomo Pharma has a strong marketing track record in the treatment of schizophrenia, including the sale of the atypical antipsychotic agent Latuda and the antipsychotic agent LONASEN Tape, both created by Sumitomo Pharma.

With the addition of XEPLION and XEPLION TRI to Sumitomo Pharma's lineup in the Psychiatry & Neurology area, Sumitomo Pharma aims to contribute to the treatment of more patients with schizophrenia.

Sumitomo Pharma will conduct promotional activities in collaboration with Janssen from around February 2025. In addition, the company also plans to assume responsibility for local distribution in the future.

These products are long-lasting solutions administered at 4 or 12-week intervals for the treatment of schizophrenia.